Core - Monoclonal Antibody

$116,356P30FY2007CANIH

Dana-Farber Cancer Inst, Boston MA

Investigators

Linked publications & trials

Paper 39713466 Paper 39666914 Paper 39605676 Paper 39593217 Paper 39536083 Paper 39532885 Paper 39484503 Paper 39389170 Paper 39322760 Paper 39168126 Paper 39160372 Paper 39107288 Paper 39042477 Paper 39025073 Paper 39024561 Paper 38996877 Paper 38992034 Paper 38979326 Paper 38979245 Paper 38942046 Paper 38924531 Paper 38889153 Paper 38861327 Paper 38815709 Paper 38805482 Paper 38777647 Paper 38712132 Paper 38701382 Paper 38700490 Paper 38688524 Paper 38659762 Paper 38650848 Paper 38641363 Paper 38600598 Paper 38579722 Paper 38546644 Paper 38491381 Paper 38486486 Paper 38472198 Paper 38464142 Paper 38336257 Paper 38331987 Paper 38327771 Paper 38297990 Paper 38295556 Paper 38293113 Paper 38141568 Paper 38061427 Paper 38060202 Paper 38014052 Paper 38012416 Paper 37995657 Paper 37992168 Paper 37961089 Paper 37874643 Paper 37870091 Paper 37819936 Paper 37772456 Paper 37729872 Paper 37725422 Paper 37698949 Paper 37653142 Paper 37596911 Paper 37586773 Paper 37577497 Paper 37563423 Paper 37541245 Paper 37463881 Paper 37414704 Paper 37339758 Paper 37279009 Paper 37272534 Paper 37258353 Paper 37249585 Paper 37248397 Paper 37208512 Paper 37163623 Paper 37139568 Paper 37059105 Paper 37011650 Paper 37010875 Paper 36939385 Paper 36914658 Paper 36847705 Paper 36831433 Paper 36823364 Paper 36812889 Paper 36811466 Paper 36797416 Paper 36750562 Paper 36747657 Paper 36681680 Paper 36669472 Paper 36658399 Paper 36418478 Paper 36410718 Paper 36189229 Paper 36150391 Paper 36125434 Paper 36017742

Abstract

The Monoclonal Antibody Core is a DF/HCC core that was approved by the CSC in May 2004. The mission of the Monoclonal Antibody Core (MAC) is to produce novel monoclonal antibodies that are directed against antigens of interest to DF/HCC investigators. These monoclonal antibodies may be useful for basic research, drug discovery and clinical applications including diagnosis, surrogate markers for disease status, response to therapy or drug toxicity. This customized service is not available at other DF/HCC institutions.

View original record on NIH RePORTER →